Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Randomized, Double-Blind, Placebo-controlled Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (Protein Expression) of Multiple Administrations of Alpha Klotho mRNA (aKLmRNA), aKL003

Authors not listed

Klothea Bio Inc · 2026

Dysbiosis Human Randomized controlled trial

Abstract

This is a Phase 1b randomized, double-blind, placebo-controlled study to assess the safety and tolerability of a proprietary aKLmRNA formulated in lipid nanoparticles. Approximately 21 subjects will be enrolled. Each subject will receive a total of two injections during the study. The cohort will consist of approximately 21 subjects, with each receiving 0.5 mg aKLmRNA (AKL003) or placebo. Subjects will be randomized in a 2:1 ratio (active treatment:placebo). The placebo will be saline, matching the active treatment in both appearance and volume.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-13 MST

Cite this

APA

Anonymous. (2026). A Randomized, Double-Blind, Placebo-controlled Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (Protein Expression) of Multiple Administrations of Alpha Klotho mRNA (aKLmRNA), aKL003. <em>Klothea Bio Inc</em>. https://clinicaltrials.gov/study/NCT07544420

Vancouver

Anonymous. A Randomized, Double-Blind, Placebo-controlled Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (Protein Expression) of Multiple Administrations of Alpha Klotho mRNA (aKLmRNA), aKL003. Klothea Bio Inc. 2026.

BibTeX

@misc{anon2026ARando, title = {A Randomized, Double-Blind, Placebo-controlled Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (Protein Expression) of Multiple Administrations of Alpha Klotho mRNA (aKLmRNA), aKL003}, author = {Anonymous}, journal = {Klothea Bio Inc}, year = {2026}, }